Abstract: Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from(a) 2, 3, or 4-pyridyl,(b) 2, 4, or 5-pyrimidinyl,(c) 2-pyrazinyl,(d) 3, or 4-pyridazinyl,(e) 3, or 4-pyrazolyl,(f) 2, or 3-tetrahydrofuranyl, and(g) 3-thienyl.

Abstract: Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from(a) 2, 3, or 4-pyridyl,(b) 2, 4, or 5-pyrimidinyl,(c) 2-pyrazinyl,(d) 3, or 4-pyridazinyl,(e) 3, or 4-pyrazolyl,(f) 2, or 3-tetrahydrofuranyl, and(g) 3-thienyl.

Abstract: Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;one of Het.sup.1 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from(a) 2, 3, or 4-pyridyl,(b) 2, 4, or 5-pyrimidinyl,(c) 2-pyrazinyl,(d) 3, or 4-pyridazinyl,(e) 3, or 4-pyrazolyl,(f) 2, or 3-tetrahydrofuranyl, and(g) 3-thienyl.

Abstract: This disclosure relates to a method of treating a neurological dysfunction in a mammal using a combination of at least one neurotransmitter enhancer and at least one serotonin receptor antagonist.

Abstract: N-oxide prodrug derivatives of 3-hydroxy morphinan and partial morphinan analgesics, agonist-antogonists, and narcotic antagonists are useful therapeutic entities which provide enhanced bioavailability of 3-hydroxy morphinans and partial morphinans from orally administered dosage forms.

Abstract: Cognitive deficiencies and/or neurological function deficits and/or mood and/or mental disturbances are treated by the administration of 3,3-disubstituted indolines. The indolines have the formula: ##STR1## wherein: p is 0 or 1;Z is O or S;R is C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.8 cycloalkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or ##STR2## V, W, X, and Y independently are H, halo, C.sub.1 -C.sub.3 alkyl, OR.sup.1, NO.sub.2, CF.sub.3, CN or NR.sup.1 R.sup.2 ;R.sup.1 and R.sup.2 independently are H or C.sub.1 -C.sub.3 alkyl; ##STR3## independently are 6-membered heterocyclic aromatic rings containing at least one nitrogen atom as a part of the ring optionally substituted with one substituent selected from the group C.sub.1 -C.sub.3 alkyl, halo, OR.sup.1 or NR.sup.1 R.sup.2 ; oran N-oxide or pharmaceutically suitable acid addition salt thereof.

Abstract: Cognitive deficiencies and/or neurological function deficits and/or mood and/or mental disturbances are treated by the administration of 3,3-disubstituted indolines. The indolines have the formula: ##STR1## wherein: p is 0 or 1;Z is O or S;R is C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.8 cycloalkyl, 2-pyridyl, 3-pyridyl, 4-pyridyl or ##STR2## V, W, X, and Y independently are H, halo, C.sub.1 -C.sub.3 alkyl, OR.sup.1, NO.sub.2, CF.sub.3, CN or NR.sup.2 R.sup.2 ;R.sup.1 and R.sup.2 independently are H or C.sub.1 -C.sub.3 alkyl;-- .circle.H and -- .circle.H' independently are 6-membered heterocyclic aromatic rings containing at least one nitrogen atom as a part of the ring optionally substituted with one substituent selected from the group C.sub.1 -C.sub.3 alkyl, halo, OR.sup.1 or NR.sup.1 R.sup.2 ; oran N-oxide or pharmaceutically suitable acid addition salt thereof.

Abstract: N-oxide prodrug derivatives of 3-hydroxy morphinan and partial morphinan analgesics, agonist-antagonists, and narcotic antagonists are useful therapeutic entities which provide enhanced bioavailability of 3-hydroxy morphinans and partial morphinans from orally administered dosage forms.

Abstract: This invention relates to a Tetrafluoroethyl Imidazole compound which shows potent antiinflammatory activity.

Abstract: 17-Substituted-6-desoxy-7,8-dihydro-6.alpha.-methylnoroxymorphone compounds corresponding to the formula ##STR1## The compounds exhibit narcotic antagonistic properties.